Read E.V.I.dently Today for current news about health policy and events, among other topics.
E.V.I.dently Today Blog
With the release of two guidance documents this week, the US Food and Drug Administration took significant steps to modernize how health care information is communicated. The final guidance released by FDA addresses communications questions as well as many of the concerns raised by NPC through our longstanding research in this area and in public testimony and comments.
Research published in the June 2018 edition of Health Affairs shows that increases in health care spending on key diseases can be attributed to several factors: the use of new and often cost-effective technologies, a shift toward preventive services, and an aging and more obese population.
The use and importance of real-world evidence (RWE) in clinical decision-making has been frequently cited by Food and Drug Administration (FDA) Commissioner Dr. Scott Gottlieb, so it’s not surprising that the topic will be top of mind at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 23rd Annual International Meeting on May 19-23 in Baltimore, Maryland. During the meeting, National Pharmaceutical Council (NPC) staff will share their expertise on real-world evidence and related issues during panel discussions, symposia and other presentations.
In his latest column for Specialty Pharmacy Times, NPC President Dan Leonard takes a closer look at a presidential panel's report on "Promoting Value, Affordability, and Innovation in Cancer Drug Treatment." The report cites NPC research on proposals including outcomes-based contracting, value assessment frameworks, and incentives to use high-value medicines and minimize out-of-pocket costs.
According to a new issue brief from VBID Health, providing pre-deductible coverage for medicines used to treat common chronic conditions could lower out-of-pocket costs and increase medication adherence for patients.
The Health Affairs Blog today published a piece from RTI International, RTI Health Solutions and National Pharmaceutical Council researchers detailing the assumptions made – and the blind spots created – by a recent Journal of the American Medical Association piece by Papanicolas et al. suggesting that the United States spends more on health care than other countries because of higher prices, higher health care salaries, and administrative costs. A more detailed look at the data underlying the claim, from the Organisation for Economic Co-operation and Development (OECD), underscores the benefits and challenges of the dataset and making cross-country comparisons.